MARKET

ADMA

ADMA

ADMA Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.370
-0.030
-2.14%
After Hours: 1.360 -0.01 -0.73% 19:17 01/18 EST
OPEN
1.390
PREV CLOSE
1.400
HIGH
1.401
LOW
1.353
VOLUME
1.36M
TURNOVER
--
52 WEEK HIGH
3.111
52 WEEK LOW
1.010
MARKET CAP
268.26M
P/E (TTM)
-2.1393
1D
5D
1M
3M
1Y
5Y
ADMA Biologics wins FDA nod for its fourth plasma collection center
ADMA Biologics (NASDAQ:ADMA) announced that the FDA approved its fourth plasma collection facility, situated in Goose Creek, South Carolina. Concurrently, the International Quality Plasma Program (“IQPP”) has also issued a
Seekingalpha · 12h ago
ADMA BioCenters Receives FDA Approval For Its Fourth Plasma Collection Center Located In Goose Creek, SC
ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it
Benzinga · 12h ago
ADMA Biologics (NASDAQ:ADMA) investors are sitting on a loss of 72% if they invested five years ago
While not a mind-blowing move, it is good to see that the ADMA Biologics, Inc. ( NASDAQ:ADMA ) share price has gained...
Simply Wall St. · 1d ago
Hikari Power Ltd Buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Sells ...
Tokyo, M0, based Investment company Hikari Power Ltd (Current Portfolio) buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Jack Henry & Associates Inc, Parker Hannifin Corp, sells Anheuser-Busch InBev SA/NV, The Kraft Heinz Co, Amarin C...
GuruFocus.com · 6d ago
These 2 “Strong Buy” Penny Stocks Are Poised to Take Off, Says Raymond James
Let’s talk about penny stocks. These are equities that trade for less than $5 per share, the very bottom of the price range. While they are priced that low for a reason – and the reasons may vary – low price in itself doesn’t mean that the stock’s fundamen...
TipRanks · 12/29/2021 15:53
FDA updates EUA for COVID convalescent plasma limiting use to certain patients
The FDA has updated the Emergency Use Authorization ("EUA") for the use of convalescent plasma as a COVID-19 treatment for patients with immunosuppressive disease or receiving immunosuppressive treatment. The FDA
Seekingalpha · 12/28/2021 22:28
BRIEF-ADMA Biologics Inc Adopts Limited Duration Stockholder Rights Plan
reuters.com · 12/21/2021 12:27
ADMA Biologics Adopts Limited Duration Stockholder Rights Plan
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today anno...
GlobeNewswire · 12/21/2021 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADMA. Analyze the recent business situations of ADMA Biologics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ADMA stock price target is 5.58 with a high estimate of 10.00 and a low estimate of 3.000.
High10.00
Average5.58
Low3.000
Current 1.370
EPS
Actual
Estimate
-0.16-0.12-0.08-0.04
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 115
Institutional Holdings: 53.02M
% Owned: 27.08%
Shares Outstanding: 195.81M
TypeInstitutionsShares
Increased
19
5.78M
New
7
3.50M
Decreased
26
5.62M
Sold Out
23
1.39M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-4.73%
Pharmaceuticals & Medical Research
-1.37%
Key Executives
Non-Executive Chairman/Independent Director
Steven Elms
President/Chief Executive Officer/Co-Founder/Director
Adam Grossman
Vice Chairman/Co-Founder/Director
Jerrold Grossman
Chief Financial Officer/Executive Vice President
Brian Lenz
Director
Young Kwon
Independent Director
Martha Demski
Independent Director
Bryant Fong
Independent Director
Lawrence Guiheen
No Data
About ADMA
ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.

Webull offers kinds of ADMA Biologics Inc stock information, including NASDAQ:ADMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMA stock methods without spending real money on the virtual paper trading platform.